Astrea Bioseparations has launched its Nereus LentiHERO lentiviral vector (LVV) purification technology commercially. Incorporating AstreAdept, the company’s proprietary nanofiber material, this solution has been created to address the challenges associated with purifying the large and fragile products used in cell and gene therapy.
AstreAdept is a proprietary bioseparations material that utilises nanofiber technology which enables biologics manufacturers to reduce process times, increase process efficiency, reduce buffer consumption, and consequently improve waste treatment costs. As a result, Astrea Bioseparations says greener, faster, and more cost-effective bioprocessing workflows are possible.
“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].”
He added, “This launch also sets the stage for a future where cutting-edge therapies can make it into the hands of patients faster and more affordably than ever.”